NCT04171219 2025-05-16
Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
M.D. Anderson Cancer Center
Phase 2 Terminated
M.D. Anderson Cancer Center
University of Nebraska
FDA Office of Orphan Products Development
Point Therapeutics